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Background: Lymphangioleiomyomatosis (LAM) is characterised by progressive airway obstruc-
tion and hypoxaemia in young women. Although sleep may trigger hypoxaemia in patients with
airway obstruction, it has not been previously investigated in patients with LAM.
Methods: Consecutive women with lung biopsy proven LAM and absence of hypoxaemia while
awake were evaluated with pulmonary function test, echocardiography, 6-min walk test, over-
night full polysomnography, and Short Form 36 health-related quality-of-life questionnaire.
Results: Twenty-five patients with (mean SD) age 45 10 years, SpO2 awake 95% 2, forced
expiratory volume in the first second (medianeinterquartile) FEV1(% predicted) 77 (47e90) and
carbonic monoxide diffusion capacity, DLCO (%) 55 (34e74) were evaluated. Six-minute walk
test distance and minimum SpO2 (medianeinterquartile) were, respectively, 447 m (411
e503) and 90% (82e94). Medianeinterquartile apnoeaehypopnoea index was in the normal
range 2 (1e5). Fourteen patients (56%) had nocturnal hypoxaemia (10% total sleep time with
SpO2 <90%), and the median sleep time spent with SpO2 <90% was 136 (13e201) min. Sleep
time spent with SpO2 <90% correlated with the residual volume/total lung capacity ratio
(rsZ 0.5, p: 0.02), DLCO (rsZ0.7, p: 0.001), FEV1 (rsZ0.6, p: 0.002). Multivariate linear
regression model showed that RV/TLC ratio was the most important functional variable related
to sleep hypoxaemia.
Conclusion: Significant hypoxaemia during sleep is common in LAM patients with normal SpO2
while awake, especially among those with some degree of hyperinflation in lung function tests.
ª 2011 Published by Elsevier Ltd.1 3171 1320; fax: þ55 11 3885 7036.
.com.br, pedromedjr@gmail.com (C.R.R. Carvalho).
1 Published by Elsevier Ltd.
Sleep desaturation and its relationship to lung function, exercise and quality of life in LAM 421Introduction chylothorax, or pneumothorax were excluded. MedicationsLymphangioleiomyomatosis (LAM) is a rare and fatal inter-
stitial lung disease, with an over world incidence ranging
from 1 to 2.5 cases in 1 million. Although the aetiology is
not completely understood, LAM is associated with
tuberous sclerosis complex (TSC) 2 gene loss of heterozy-
gosis and consequently loss in the balance between
hamartin/tuberin, proteins synthesised by TSC-1/TSC-2 and
extremely important in the regulation of cellular prolifer-
ation and apoptosis. LAM occurs almost exclusively in
women of childbearing age, sometimes with mild symptoms
as dry cough and wheezing which may lead to incorrect
diagnosis of asthma or COPD in no smoking women. The
most typical clinical findings, however, are dyspnoea and
recurrent spontaneous pneumothorax.1e5 LAM is charac-
terised by progressive airway obstruction, and forced
expiratory volume in 1 s (FEV1) is the main variable used to
determine disease severity and treatment follow-up.6
Reduced carbon monoxide diffusion capacity (DLCO),
decreased maximal oxygen consumption (VO2max), and
progressive worsening of hypoxaemia are common
throughout the disease evolution. Although there are no
established medical treatments, reports of anti-hormonal
(GnRH analogue), rapamycin and doxycycline use are
present in the medical literature.1e10
Hypoxaemia during exercise represents one of the first
functional impairments in patients with LAM.3 In addition to
physical exercise,11,12 sleep may also trigger hypoxaemia.
For instance, patients with chronic obstructive pulmonary
disease (COPD)9,10 with similar pulmonary functional
impairments (i.e., hyperinflation and reduced DLCO) may
experience hypoxaemia during sleep.13 Nocturnal hypo-
xaemia may be associated with sleep efficiency decline,
quality-of-life impairments, and development of pulmonary
hypertension.13e15 Nonetheless, to the best of our knowl-
edge, sleep has not been previously investigated in patients
with LAM.
The aim of this study was to evaluate sleep and
nocturnal desaturation in patients with LAM and its relation
to functional capacity, exercise, and quality-of-life vari-
ables in an outpatient population with LAM. We also eval-
uated nocturnal desaturation and its relation to pulmonary
hypertension.Methods
Study population
Consecutive women with LAM attending the Pulmonary
Division of the Hospital das Clinicas, University of Sa˜o
Paulo, Brazil, were prospectively screened from January
2005 to May 2008. Eligible subjects had (1) a diagnosis of
LAM confirmed by surgical lung biopsy reviewed by
pathologists with pulmonary expertise from the Depart-
ment of Pathology of the University of Sa˜o Paulo Medical
School and (2) clinical stability for at least 4 weeks, defined
by the absence of hospitalisation, antibiotic use, or
increase in dyspnoea. Patients using oxygen due to resting
hypoxia (arterial oxygen saturation <90%), presence ofand general treatment were not modified during the
protocol evaluation that was performed within an interval
no longer than 8 weeks. Patients who failed to perform all
functional evaluations were further excluded. Written
informed consent was obtained from all subjects, and the
Institutional Review Board (www.saude.gov.br/sisnep)
approved the study “Estudo da func¸a˜o pulmonar, sono,
exercı´cio e qualidade de vida de pacientes com linfangio-
leiomiomatose pulmonary” number: 2645.0.015.000-05.
Pulmonary function test (PFT)
Lung volumes, flow rates, and DLCO were measured using
a computerised system e Collins Plus Pulmonary Function
Testing Systems (Warren E. Collins, Inc., Braintree, MA,
USA) according to international guidelines recommenda-
tions.16,17 Post-bronchodilator volumes were registered.
Percentages of predicted values were derived from stan-
dard equations.18,19 All tests were done in the same respi-
ratory physiology laboratory under a barometric pressure
around 695 mmHg. Baseline dyspnoea index was used to
evaluate resting dyspnoea.20
Six-minute walk test (6MWT)
Six-minute walk tests (6MWT) were conducted in a 50-m
long flat straight corridor in the outpatient clinic of Hospital
das Clinicas by a respiratory therapist trained in basic life
support. Every patient performed the test according to the
ATS recommendations.21 No supplemental oxygen was
used. Distance in metres, continuous oxygen saturation
level, DSpO2 (D: initial SpO2 final SpO2), and Borg index
(limbs and dyspnoea) were registered. Predicted distances
were calculated according to reference equations for
healthy adults.22
Polysomnography
All participants underwent a standard overnight poly-
somnography (EMBLA; Flaga hf. Medical Devices, Reykjavik,
Iceland), including electroencephalography, electroocu-
lography, electromyography, oximetry, nasal thermistor,
a cannula for airflow and ribcage and abdominal belts to
detect breathing movements as previously described.23
Apnoea was defined as complete cessation of airflow for
at least 10 s. Hypopnoea was defined as a decrease to less
than 70% of baseline on either inductance plethysmography
channel or nasal cannula airflow, for 10 s or longer and
associated with 4% desaturation or more. The
apnoeaehypopnoea index (AHI) was calculated as the total
number of respiratory events (apnoeas plus hypopnoeas)
per hour of sleep. The AHI cut-off for no obstructive sleep
apnoea (OSA), mild to moderate OSA, and severe OSA was,
respectively, less than 5, 5e15, and more than 15 events
per hour of sleep. Other measures included the magnitude
of nocturnal oxygen desaturations, expressed by minimum
nocturnal SpO2 and total time with SpO2 less than 90% (time
SpO2 <90%). Clinically relevant nocturnal desaturation was
defined as a fall in SpO2 below 90% for at least 10% of total
sleep time.24
422 P. Medeiros et al.Echocardiography
Echocardiographic images were obtained in the para-
sternal long-axis and short-axis, the apical long-axis, and
the apical 4-chamber view, according to current stan-
dards, by personnel blinded to the results of the poly-
somnography and PFT. Left atrial diameter (LAD), left
ventricle (LV) end-diastolic internal dimension (LVEDD), LV
end-systolic internal dimension, interventricular septal
thickness (IVST), and LV posterior wall thickness (LVPWT)
were determined from M-mode measurements. In addi-
tion, we obtained the LV ejection fraction and LV mass
measurements. Echocardiography was performed accord-
ing to the Brazilian Society of Cardiology Guidelines.25
Ejection fraction lower than 65% and systolic arterial
pulmonary pressure higher than 40 mmHg were consid-
ered abnormal.
Questionnaires
Each subject completed the Short Form 36 (SF-36)26,27
questionnaire measuring generic health-related quality of
life (HRQL); the baseline dyspnoea and Borg index (BDI)
measuring basal and exercise shortness of breath, respec-
tively,20,28 Epworth Sleepiness Score29 and Berlin30
measuring excessive daytime somnolence and risk to OSA,
respectively.
Analysis
Continuous variables are presented as mean (SD) or median/
interquartile range (IQR), and categorical variables are pre-
sented as frequency (percentage) except where stated. To
investigate the possible association between oxygen desa-
turation during sleep and functional variables determined
while awake, Spearman correlation coefficients wereFigure 1 Awacalculated between time SpO2 <90% on PSG with functional
parameters while awake, including PFTand 6MWT variables.
Differences across groups were compared using theWilcoxon
Rank Sum test where distribution was skewed. Stepwise
multiple logistic regressions were used to select the signifi-
cant predictors for oxygen desaturation. Model assumptions
were assessed by residual plots. Data were analysed with
statistical software (SPSS 14.0; SPSS; Chicago IL). All p values
are two-tailed, and values<0.05 are considered statistically
significant.Results
Demographic and functional characteristics of the
population
Thirty women were initially evaluated. Five were excluded
because they did not fulfil biopsy review criteria (nZ 2),
were using continuous oxygen therapy due to awake
hypoxaemia (nZ 1), and failed to perform all tests (nZ 2).
Therefore, a total of 25 patients completed the protocol
(Fig. 1). The time lag between LAM diagnosis and study
evaluation was 2 0.8 years. The demographic and func-
tional variables, including pulmonary function test and
6MWT of the population studied are presented in Table 1. At
the time of the study, all but three patients were being
treated with anti-hormonal therapy (GnRH analogue),
which lead to a state of chemical menopause. Patients did
not have hypoxaemia while awake (Table 1), due to the
study design, and the baseline dyspnoea index was in the
normal range [median: 25e75%, interquartile: 3 (2e4)]. As
expected, pulmonary function tests revealed an obstructive
pattern with reductions in predicted FEV1 and DLCO. At the
end of the 6MWT, median/IQR Borg dyspnoea was 3
(2e4.5), and 11 patients had developed SpO2 <90%
(mean SD e minimal 6MWT SpO2 77 7%).ken stage.
Table 1 Baseline patient characteristics of the population
studied.
Median (IQR)
Age (years) 45 (35e60)
BMI (kg/m2) 24 (19e35)
FEV1 (% predicted) 77 (47e90)
FVC (% predicted) 87 (76e99)
FEV1/FVC (% predicted) 77 (52e82)
RV/TLC (% predicted) 102 (92e137)
DLCO (mL/min/mmHg) (% predicted) 55 (34e74)
Awaken resting SpO2 (%) 95 (94e96)
Distance walked 6MWT (m) 447 (411e503)
Distance walked 6MWT (% predicted) 72 (62e81)
Minimum SpO2, 6MWT (%) 90 (82e94)
Baseline dyspnoea index 3 (2e4)
BMI: body mass index; FEV1: forced expiratory volume in one
second; FVC: forced vital capacity; FEV1/FVC: ratio between
FEV1 and FVC; RV: residual volume (L); TLC: total lung capacity
(L); RV/TLC: ratio between RV and TLC; DLCO: diffusion capacity
for carbon monoxide (mL/min/mmHg); 6MWT: 6-minute walk
test; and SpO2: transcutaneous oxygen haemoglobin saturation.
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Polysomnography findings are summarised in Table 2.
Generally, sleep efficiency, median apnoeaehypopnoea
index (AHI), and AHI in REM were in the normal range. Four
patients had an AHI >5 events/h (mean SD e AHI
10.2 4.9). Despite the absence of hypoxaemia while
awake and the absence of significant sleep apnoea disorder,
patients frequently had oxygen desaturation (Table 2).
While ventilation and oxygen saturation remained stable
during most of the slow wave sleep phase (S3eS4), desa-
turation was much more common during REM sleep, with
irregular ventilatory pattern, especially during clusters of
eye movements. Figs. 1e5 represent the most common
polysomnography pattern observed among this set of
patients with LAM. Based on oxygen saturation, patients
were stratified into nondesaturators and desaturatorsTable 2 Sleep characteristics in the population studied
(nZ 25).
Median (IQR)
Total time of sleep (min) 402 (356e432)
Sleep efficiency (%) 87 (81e90)
Sleep latency (min) 13 (5e19)
REM latency (min) 115 (75e169)
S1þ S2 (%) 63 (53e81)
S3þ S4 (%) 14 (6e20)
REM (%) 17 (10e19)
Apnoea index (events/h) 2 (1e5)
Apnoea e REM (events/h) 3 (1e15)
Minimum SpO2 (%) 83 (81e88)
% Time SpO2 <90% (%) 31.2 (0e60.2)
Time SpO2 <90% (min) 136 (13e201)
S1þ S2: superficial sleep stages; S3þ S4: slow wave sleep
stages; REM: rapid eye movement stage; and time SpO2 <90%:
time of sleep with SpO2 less than 90%.during sleep (Table 3). Nondesaturators and desaturators
were similar regarding age and BMI and had a slightly lower
SpO2 while awake with no statistical significance. In
contrast, desaturators had significantly lower FEV1, DLCO,
final SpO2 in 6MWT, and a higher RV/TLC ratio.
Echocardiography
Twenty-one patients of the total of 25 performed thoracic
echocardiography. The 4 patients who were not able to
undergo echocardiography, due to transportation limita-
tions, had pulmonary function similar to the median values
of the whole population (data not shown). Left ventricular
ejection fraction was 70 6%, and no pulmonary hyper-
tension or LV systolic dysfunction was found in our pop-
ulation (Table 4).
Nocturnal hypoxaemia and relation to functional
variables
FEV1, RV/TLC, DLCO and final SpO2 in 6MWT yielded
significant correlation coefficients to time SpO2 <90%.
Results are summarised in Tables 3 and 4. Multivariate
linear regression model yielded that among these func-
tional covariates RV/TLC was the remaining variable
statistically related to nocturnal sleep hypoxaemia in the
model (Table 5).
Questionnaires
Two SF-36 domains (physical and emotional roles) were the
most impaired domains in the whole population. Both had
statistically significant differences and were worse in sleep
desaturators than in nondesaturators (Table 6). The
Epworth Sleepiness Scale (ESS) results yielded that 2
women in both groups presented a score higher than (8:1)
nondesaturators (age 35 and 40), EES (13,17), apnoea index
(5.1 and 4.0); desaturators (age 31 and 36), EES (9,10),
apnoea index (6.0 and 5.5) [no significant statistical
difference was observed pZ 0.74]. Berlin questionnaire did
not yield differences among both groups too.
Discussion
This is the first study that systematically evaluated sleep in
patients with LAM. Our study conveys several novel find-
ings. First, 56% of the patients had significant nocturnal
hypoxaemia during sleep despite normal oxygen saturation
while awaken. Second, despite the menopause induced by
GnRH analogue treatment, obstructive sleep apnoea was
not common among patients with LAM. Third, nocturnal
hypoxaemia did not correlate with demographic charac-
teristics or awaken SpO2.
Lastly, nocturnal hypoxaemia correlated with pulmonary
function variables, including FEV1, RV/TLC, DLCO, and
minimum SpO2 on 6MWT. Multivariate analysis showed that
nocturnal hypoxaemia correlation to RV/TLC ratio was the
most important one.
These findings indicate that nocturnal desaturation is
a much more common problem in clinical practice than
Figure 2 S3eS4 regular ventilation.
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ment based only on resting PFT and oximetry. The strength
of it is that we consecutively screened an entire LAM
outpatient clinic population with resting, exercise, and
nocturnal oximetry. The majority of patients were not in an
advanced disease stage, and we looked for possible earlier
predictor variables of functional deterioration. Patients
had mild obstructive ventilatory disturbance and moderate
impairment in DLCO, and none of them had severe
obstructive sleep apnoea (OSA). Because the GnRH
analogue induced menopause could be responsible for
increasing sleep apnoea, OSA was a concern for us during
the design of study.31 This finding ensured us about the
safety of anti-hormonal treatment in not increasing the
incidence of OSA.Figure 3 REM e hLAM is structurally characterised by gradual replace-
ment of lung parenchyma by thin wall cysts, which func-
tionally leads to progressive obstruction, diffusion
impairment and finally hyperinflation detected in lung
function tests. Our set of patients had mild to moderate
obstructive and diffusion disorder, without rest hypo-
xaemia, and nocturnal hypoxaemia was mainly detected
during irregular ventilation presented in REM sleep. There
are several mechanisms underlying nonapnoeic oxygen
desaturation during sleep that may explain why patients
with LAM and without rest hypoxaemia desaturate during
sleep. They include impairments in: functional residual
capacity, ventilatory responses to hypoxia and hyper-
capnia, respiratory mechanical effectiveness, arousal
responses, respiratory muscle fatigue, chemical respiratoryypoventilation.
Figure 4 Transitional ventilatory pattern: S2eREM.
Sleep desaturation and its relationship to lung function, exercise and quality of life in LAM 425drive, upper airway resistance and also in the position of
baseline saturation values on the oxyhaemoglobin dissoci-
ation curve.31e35
Among the functional variables evaluated, the RV/TLC
ratio was the main variable related to nocturnal sleep
desaturation. For instance, hyperinflation may be directly
related to the impairment in the ventilation to perfusion
ratio that occurs during recumbence in sleep in this set of
patients. It may also intensify hypoventilation, because
tonus is reduced and auxiliary respiratory muscles are
inactivated. Although, we did not measure exhaled CO2,
and therefore were not able to conclude that hypo-
ventilation was the main phenomenon related to nocturnal
sleep desaturation, the respiratory pattern (Figs. 1e4)
observed during polysomnography suggests thatFigure 5 Hyhypoventilation might be an important concern in women
with LAM during sleep.
Since sleep had not been properly evaluated in LAM, and
pulmonary function test results in LAM are very similar to
those of COPD, we may infer that there may be some
common physiologic mechanisms. COPD patients desatu-
rate during sleep even in the absence of OSA, and one of
the most important mechanisms is hypoventilation. Several
studies have shown that recurrent transient hypoxaemia
during sleep is frequent in patients with COPD.13e15
Nocturnal hypoxaemia is particularly marked in patients
with “blue and bloated” clinical phenotype and frequently
occurs during REM sleep. The measurement of minute
ventilation with a pneumotachograph and oxygen satura-
tion with pulse oximetry in a group of patients with severepnogram.
Table 3 Patient characteristics stratified according to the absence or presence of nocturnal hypoxaemia during sleep.
Characteristics Desaturators (nZ 14) Nondesaturators (nZ 11) p
Age (years) 45 (42e55) 45 (36e53) 0.18
BMI (kg/m2) 23 (20e28) 23 (23e25) 0.75
MNSpO2 81 (76e83) 90 (85e90) 0.04
FEV1 (L) 1.3 (0.8e1.9) 2.4 (2.2e2.7) 0.02
FVC (L) 2.5 (2e2.9) 3.2 (2.6e3.8) 0.14
TLC (L) 5.0 (4.1e5.9) 4.9 (4e5.7) 0.35
RV (L) 2.3 (1.6e3.2) 1.5 (1.1e2.0) 0.17
RV/TLC 0.4 (0.40e0.60) 0.3 (0.29e0.34) 0.04
DLCO (mL/min/mmHg) 9.2 (4.6e13.3) 18 (16e20) 0.03
Awake SpO2 (%)
a 94 2 97 1 0.17
Apnoea index (events/h) 2.7 (1.3e6.7) 1.5 (0.7e7) 0.27
Minimum saturation 6MWTa 80 8 93 4 0.018a
Distance (m) 463 (353e503) 460 (420e541) 0.74
MNS: minimum nocturnal saturation; BMI: body mass index; FEV1: forced expiratory volume in one second; FVC: forced vital capacity;
RV: residual volume (L); TLC: total lung capacity (L); RV/TLC: ratio between RV and TLC; DLCO: diffusion capacity for carbon monoxide
(mL/min/mmHg); and time SpO2 <90%: time of sleep with SpO2 less than 90%.
Data are expressed as Median (IQR).
a Mean SD.
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REM sleep and 40% lower oxygenation during REM sleep
than during the awake state, primarily due to reduced tidal
volume.36,37
Tidal volume small reductions, with little or no change in
breathing frequency, are present from wakefulness to
NREM sleep reducing alveolar ventilation. This phenomenon
leads to a mild increase in arterial CO2 tension of
2e8 mmHg, despite a 10e30% fall in metabolic CO2
production. Ventilation decline is particularly more
pronounced during REM sleep, and severe oxygen desatu-
ration especially occurs during bursts of rapid eye move-
ments and might be intensified by the misbalance in
ventilation-perfusion due to recumbence. Since the venti-
latory response to hypoxia decreases by 33% during NREM
sleep many subjects remain asleep with arterial saturation
as low as 70% with no apparent NREMeREM differences.36,37
This mechanism may be responsible for the normal sleepTable 4 Correlations between nocturnal sleep desatura-
tion and functional, exercise, and echocardiographic
variables.
Measure MNS Time SpO2 <90%
rs rs
% FEV1 0.6 (pZ 0.02) 0.6 (pZ 0.002)
% RV/TLC 0.5 (pZ 0.02) 0.5 (pZ 0.02)
% DLCO 0.7 (pZ 0.0001) 0.7 (pZ 0.001)
Minimum
saturation 6MWT
0.7 (pZ 0.0001) 0.6 (pZ 0.02)
p< 0.05 Wilcoxon test; MNS: minimum nocturnal saturation;
FEV1: forced expiratory volume in one second in litres; DLCO:
diffusion capacity for carbon monoxide (mL/min/mmHg); RV/
TLC: ratio between residual volume in litres and total lung
capacity in litres; 6MWT: 6-min walk test; SpO2: haemoglobin
oxygen saturation; and time SpO2 <90%: time of sleep with SpO2
less than 90%. rsZ Spearman correlation coefficient.efficiency found in our group of patients (88%), despite the
fact that they did or did not desaturate during sleep.
In addition, chronic hypoxaemia has been associated
with development of pulmonary hypertension, mainly
through enhancement of prevascular resistance (potassium
channel blockage and intracellular calcium influx) and
misbalance in serotonin and endothelin actions.39 Increased
pulmonary arterial pressure has been detected during sleep
in patients with COPD, and pulmonary hypertension and cor
pulmonale are commonly seen in this set of patients.40
Therefore, desaturation during sleep may represent an
important predictor of severity and influence on patients
with LAM quality of life, morbidity, and mortality as in
COPD.38e42
According to analysis of the questionnaires, we found
that patients with nocturnal desaturation had more limi-
tations in physical and emotional domains than the ones
who did not. Impairments in quality of life related to healthTable 5 Multivariate analysis e linear regression e
between time SpO2 <90% during polysomnography and
functional and 6MWT variables.
Variable B 95% IC
Lower
bound
95% IC
Upper
bound
Significance p
% DLco 0.233 5.376 2.668 0.484
% FEV1 0.865 9.705 1.295 0.124
% RV/TLC 0.565 4.453 0.134 0.039
MNS 6MWT 0.114 14.386 17.536 0.836
R2Z 0.512; pZ 0.022.
DLCO: diffusion capacity for carbon monoxide (mL/min/mmHg);
FEV1: forced expiratory volume in one second in litres; RV/TLC:
ratio between residual volume in litres and total lung capacity
in litres; MNS: minimum nocturnal saturation; 6MWT: 6-min
walk test; and SpO2: transcutaneous oxygen haemoglobin
saturation.
Table 6 Questionnaire SF-36 stratified according to the presence or absence of oxygen desaturation during sleep.
All patients (nZ 25) Desaturator (nZ 14) Nondesaturator (nZ 11) p
Physical functioning 55 (40e70) 55 (35e72.5) 57.5 (42.5e69) 0.73
Physical role 50 (12.5e100) 25 (0e100) 75 (31.2e100) 0.01
Pain 67.5 (46.3e90) 77.5 (46.3e95) 67.5 (50e84.4) 0.24
General health 70 (47.5e75) 70 (47.5e77.5) 70 (35e75) 0.94
Vitality 72 (62e80) 72 (59e80) 74 (55e85) 0.9
Social functioning 75 (50e87.5) 75 (50e8.5) 68.8(53e84.4) 0.67
Emotional role 33 (0e100) 33 (0e66.5) 83 (33e100) 0.04
Mental health 65 (55e80) 65 (57.5e77.5) 65 (55e83.4) 0.94
Data are expressed as median (interquartile).
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tural sleep disturbance and other variables not evaluated
may influence health perceptions. However, there might be
a direct relation between HRQOL impairment and nocturnal
hypoxaemia, although not precisely demonstrated in other
obstructive populations (COPD), which should make us pay
great attention to this association in patients with LAM.
Our study has limitations that warrant discussion. First,
it is possible that because of our sample size and mild
functional impairments pulmonary hypertension was not
observed and therefore no association with nocturnal
hypoxaemia could be observed. Second, we do not have
data about arterial blood gas either in rest or in exercise,
which would have helped us evaluate respiratory functional
status. Third, although we believe that hypoventilation was
the main mechanism leading to nocturnal hypoxaemia, CO2
levels were not measured during sleep, and so we are not
able to confirm this hypothesis. However, the ventilatory
pattern detected during REM versus NREM sleep may lead us
to hypothesise that this could be an important mechanism
associated with sleep desaturation.
In conclusion, in a survey of a LAM outpatient pop-
ulation, isolated nocturnal desaturation was very common
and was present in more than half of patients. Hyperinfla-
tion was the main functional characteristic related to
nocturnal sleep hypoxaemia. HRQOL impairment was more
frequent among desaturators; physical and emotional roles
were the most disturbed domains. Desaturation was more
intense during sleep than during 6MWT, and patients with
nocturnal desaturation did not have impaired sleep effi-
ciency. Therefore, to stratify LAM severity and understand
its progression, we believe that nocturnal oxygen desatu-
ration during sleep must be investigated and ruled out in all
patients with LAM.Ethical approval
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